Diabetic neuropathy is one of the most common chronic complications of diabetes,including diabetic peripheral neuropathy,central neuropathy and autonomic neuropathy,but its etiology and pathogenesis is unclear.Glucagon-like peptide-1(GLP-1) is a new target for the drug of type 2 diabetes.It has the functions of lowering blood glucose,improving β cell function,delaying gastric emptying, enhancing satiety,protecting cardiovascular and nervous tissues and other effects.GLP-1 receptor agonist(GLP-1RA),as a novel hypoglycemic agent, has become a hot spot in the field of treatment of diabetes and its chronic complications.Among them,GLP-1RA can improve the symptoms of diabetic neuropathy by accelerating nerve conduction velocity,increasing the number of axons, providing nerve cells with nutrition factors,inhibiting neuronal apoptosis,antagonizing oxidative stress and other potential effects,and will provide a new treatment of diabetic neuropathy.%糖尿病神经病变是糖尿病最常见的慢性并发症之一,主要包括糖尿病周围神经病变、中枢神经病变以及自主神经病变,但其病因和发病机制尚不清楚.胰高血糖素样肽1(GLP-1)是2型糖尿病药物作用的新靶点,具有降低血糖、改善β细胞功能、延缓胃排空、增强饱腹感和保护心血管及神经组织等多种功效.其类似物GLP-1受体激动剂(GLP-1RA),作为新型降糖药物,成为糖尿病及其慢性并发症治疗领域的研究热点.其中,GLP-1RA可通过加快神经传导速度,增加神经轴突的数量,为神经细胞直接提供营养因子,抑制神经细胞凋亡,拮抗氧化应激等多种潜在作用改善糖尿病神经病变的症状,将为糖尿病神经病变的治疗提供新方法.
展开▼
